Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 130Radiotherapy 86Bevacizumab 43Radiation 31Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gefitinib 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gliosarcoma × TPI-287 × Clear all
NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡